PUBLICATIONS

1. Szumowski, M. (2020). OncoArendi Therapeutics as Platform-based Polish Biotech Company–A Case Study. Technology Transfer and Entrepreneurship, 7(1), 74-84.

2. Shi, JY., Huang, H., Zhang, YN. et al. BMCMDA: a novel model for predicting human microbe-disease associations via binary matrix completion. BMC Bioinformatics 19, 281 (2018). https://doi.org/10.1186/s12859-018-2274- 3

3. Huber V, Di Guardo L, Lalli L, et al Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. Journal for ImmunoTherapy of Cancer 2021;9:e001167. https://doi.org/10.1136/jitc-2020-001167

4. Daveri, E., Vergani, E., Shahaj, E., Bergamaschi, L., La Magra, S., Dosi, M., … & Huber, V. (2020). microRNAs Shape Myeloid Cell[1]Mediated Resistance to Cancer Immunotherapy. Frontiers in Immunology, 11.

5. Swider, E., Maharjan, S., Houkes, K., van Riessen, N. K., Figdor, C., Srinivas, M., & Tagit, O. (2019). Forster resonance energy transfer[1]based stability assessment of PLGA nanoparticles in vitro and in vivo. ACS applied bio materials, 2(3), 1131-1140.

6. Herrmann, V. L., Wieland, D. E., Legler, D. F., Wittmann, V., & Groettrup, M. (2016). The STEAP1262–270 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA‐A* 0201 transgenic mice—A new approach to immunotherapy against prostate carcinoma. The Prostate, 76(5), 456-468.

7. Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., Milione, M., Porcu, L., Proto, C., Pruneri, G., Signorelli, D., Sangaletti, S., Sfondrini, L., Storti, C., Tassi, E., Bardelli, A., … Garassino, M. C. (2019). Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(3), 989–999. https://doi.org/10.1158/1078-0432.CCR-18-1390

8. Huber, V., Vallacchi, V., Fleming, V., Hu, X., Cova, A., Dugo, M., Shahaj, E., Sulsenti, R., Vergani, E., Filipazzi, P., De Laurentiis, A., Lalli, L., Di Guardo, L., Patuzzo, R., Vergani, B., Casiraghi, E., Cossa, M., Gualeni, A., Bollati, V., Arienti, F., … Rivoltini, L. (2018). Tumor[1]derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. The Journal of clinical investigation, 128(12), 5505–5516. https://doi.org/10.1172/JCI98060

9. Koerner, J., Horvath, D., & Groettrup, M. (2019). Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy. Frontiers in immunology, 10, 707. https://doi.org/10.3389/fimmu.2019.00707

10. Operti, M. C., Dölen, Y., Keulen, J., van Dinther, E., Figdor, C. G., & Tagit, O. (2019). Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles. Pharmaceutics, 11(11), 590. https://doi.org/10.3390/pharmaceutics11110590

11. Dölen, Y., Valente, M., Tagit, O., Jäger, E., Van Dinther, E. A., van Riessen, N. K., … & Figdor, C. G. (2020). Nanovaccine administration route 9 is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses. Oncoimmunology, 9(1), 1738813.

12. Valente, M., Dölen, Y., van Dinther, E., Vimeux, L., Fallet, M., Feuillet, V., & Figdor, C. G. (2019). Cross-talk between iNKT cells and CD8 T cells in the spleen requires the IL[1]4/CCL17 axis for the generation of short-lived effector cells. Proceedings of the National Academy of Sciences of the United States of America, 116(51), 25816–25827. https://doi.org/10.1073/pnas.1913491116